S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
NASDAQ:NBIX

Neurocrine Biosciences - NBIX Stock Forecast, Price & News

$110.03
+2.03 (+1.88%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$108.44
$110.90
50-Day Range
$107.99
$127.06
52-Week Range
$75.25
$129.29
Volume
1.15 million shs
Average Volume
872,826 shs
Market Capitalization
$10.58 billion
P/E Ratio
193.04
Dividend Yield
N/A
Price Target
$122.24

Neurocrine Biosciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
11.6% Upside
$122.82 Price Target
Short Interest
Healthy
2.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.61
Upright™ Environmental Score
News Sentiment
0.37mentions of Neurocrine Biosciences in the last 14 days
Based on 25 Articles This Week
Insider Trading
Selling Shares
$13.60 M Sold Last Quarter
Proj. Earnings Growth
108.20%
From $1.83 to $3.81 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

457th out of 1,028 stocks

Biological Products, Except Diagnostic Industry

76th out of 168 stocks

NBIX stock logo

About Neurocrine Biosciences (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The firm's product includes INGREZZA. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Receive NBIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.

NBIX Stock News Headlines

Pliant Therapeutics Gaps 34% Higher: More Upside To Come? (NBIX)
Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Neurocrine Biosciences Q4 2022 Earnings Preview
Neurocrine Biosciences Earnings Preview
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
NBIX Neurocrine Biosciences, Inc.
Voyager, Neurocrine sign new deal worth up to $4.2B
See More Headlines
Receive NBIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.

NBIX Company Calendar

Last Earnings
11/01/2021
Today
2/05/2023
Next Earnings (Confirmed)
2/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:NBIX
CUSIP
64125C10
Employees
900
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$122.82
High Stock Price Forecast
$150.00
Low Stock Price Forecast
$94.00
Forecasted Upside/Downside
+11.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
16 Analysts

Profitability

Net Income
$89.60 million
Pretax Margin
5.92%

Debt

Sales & Book Value

Annual Sales
$1.13 billion
Cash Flow
$1.24 per share
Book Value
$14.48 per share

Miscellaneous

Free Float
91,904,000
Market Cap
$10.58 billion
Optionable
Optionable
Beta
0.49

Key Executives

  • Kevin Charles GormanKevin Charles Gorman
    Chief Executive Officer & Director
  • Bill Wilson
    Vice President-Information Technology & Operations
  • Matthew C. AbernethyMatthew C. Abernethy
    Chief Financial Officer
  • Dimitri E. GrigoriadisDimitri E. Grigoriadis
    Chief Research Officer
  • Eiry W. RobertsEiry W. Roberts
    Chief Medical Officer













NBIX Stock - Frequently Asked Questions

Should I buy or sell Neurocrine Biosciences stock right now?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last twelve months. There are currently 6 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NBIX shares.
View NBIX analyst ratings
or view top-rated stocks.

What is Neurocrine Biosciences' stock price forecast for 2023?

16 Wall Street analysts have issued 1-year target prices for Neurocrine Biosciences' shares. Their NBIX share price forecasts range from $94.00 to $150.00. On average, they anticipate the company's stock price to reach $122.82 in the next twelve months. This suggests a possible upside of 11.6% from the stock's current price.
View analysts price targets for NBIX
or view top-rated stocks among Wall Street analysts.

How have NBIX shares performed in 2023?

Neurocrine Biosciences' stock was trading at $119.44 at the beginning of 2023. Since then, NBIX stock has decreased by 7.9% and is now trading at $110.03.
View the best growth stocks for 2023 here
.

Are investors shorting Neurocrine Biosciences?

Neurocrine Biosciences saw a increase in short interest in January. As of January 15th, there was short interest totaling 2,590,000 shares, an increase of 15.1% from the December 31st total of 2,250,000 shares. Based on an average daily volume of 819,500 shares, the days-to-cover ratio is presently 3.2 days. Currently, 2.8% of the shares of the stock are sold short.
View Neurocrine Biosciences' Short Interest
.

When is Neurocrine Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 6th 2023.
View our NBIX earnings forecast
.

How can I listen to Neurocrine Biosciences' earnings call?

Neurocrine Biosciences will be holding an earnings conference call on Monday, February 6th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced its earnings results on Monday, November, 1st. The company reported $0.23 earnings per share for the quarter, missing the consensus estimate of $0.51 by $0.28. The business had revenue of $296 million for the quarter, compared to the consensus estimate of $297.02 million. Neurocrine Biosciences had a net margin of 4.19% and a trailing twelve-month return on equity of 4.06%. The business's revenue for the quarter was up 14.5% on a year-over-year basis. During the same period last year, the business earned ($0.62) earnings per share.

What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO?

11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM).

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Congress Asset Management Co. MA (0.95%), Allspring Global Investments Holdings LLC (0.52%), Tobam (0.30%), Sumitomo Mitsui Trust Holdings Inc. (0.30%), New York State Common Retirement Fund (0.24%) and Assenagon Asset Management S.A. (0.22%). Insiders that own company stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops, Stephen A Sherwin and William H Rastetter.
View institutional ownership trends
.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $110.03.

How much money does Neurocrine Biosciences make?

Neurocrine Biosciences (NASDAQ:NBIX) has a market capitalization of $10.58 billion and generates $1.13 billion in revenue each year. The company earns $89.60 million in net income (profit) each year or $0.57 on an earnings per share basis.

How many employees does Neurocrine Biosciences have?

The company employs 900 workers across the globe.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The official website for the company is www.neurocrine.com. The company can be reached via phone at (858) 617-7600, via email at ir@neurocrine.com, or via fax at 858-617-7602.

This page (NASDAQ:NBIX) was last updated on 2/5/2023 by MarketBeat.com Staff